Check out our headquarters and facilities located in Canary Wharf! Join us on a walk-through tour🚶 🛏️ Built for purpose 50-bed quarantine unit 🔬 State-of-the-art laboratory with fantastic views 💼 Corporate offices & staff welfare area #HVO #HCT #CHIM #QuarantineFacility #Labs #Views #London #CanaryWharf
hVIVO
Biotechnology Research
London, England 11,726 followers
The world leader in testing infectious and respiratory disease vaccines & therapeutics using human challenge trials.
About us
hVIVO plc (ticker: HVO) is a fast growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.
- Website
-
http://www.hvivo.com
External link for hVIVO
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- London, England
- Type
- Public Company
- Founded
- 1989
- Specialties
- clinical trials, uk clinical trials, clinical research, challenge models, human challenge models, human volunteer research, respiratory disease research, medical research, asthma studies, copd, influenza, human models of disease, clinical research, challenge studies, human challenge trials, RSV, malaria, HRV, Respiratory syncytial virus, Human rhinoviruse, lab services, and covid 19
Locations
-
Primary
Get directions
40 Bank Street
London, England E14 5NR, GB
Employees at hVIVO
Updates
-
Happy New Year!🎊 We look forward to another exciting year at the hVIVO Group in 2025 as we continue on our mission to deliver today’s healthcare by empowering tomorrow’s innovation. 🚀 We wish you all the best for 2025! #HVO #HappyNewYear #AIM
-
2024 was an incredible year of achievements for the hVIVO Group🎉. Over the past year we have moved to our new HQ in Canary Wharf, the world's largest commercial human challenge unit, and successfully expanded our service offering. Check out some of the highlights of the year in our 2024 Year in Review! hVIVO is committed to transforming global healthcare by revolutionising drug development process through scientific innovation and ingenuity. Here's to even more milestones in 2025! 🥂 #HVO #YearInReview #Goodbye2024
-
Our CEO Yamin 'Mo' Khan caught up with Vox Markets on a transformational year for hVIVO: ⏪ Recap on 2024 🏙️ World’s largest commercial challenge facility in Canary Wharf 🔬 Expanded services & launch of hLAB 🚀 2025 & beyond - targeting £100m revenue by 2028 Watch it here: https://lnkd.in/eFdCiFYi #HVO #VOXMarkets #NewYearNewMe #AIM
hVIVO Year in Review: Milestones, Growth and 2025 Ambitions
https://www.youtube.com/
-
As we wrap up a remarkable year of progress at hVIVO Group — with the opening of our state-of-the-art facility and the expansion of our services — we extend warm holiday wishes to our dedicated team, clients, investors, followers, industry colleagues and our FluCamp volunteers who make it all possible. 🎄🎅 #HVO #Christmas #MerryChristmas #SeasonsGreetings
-
-
Check out 👀 the top three photos awarded 1st, 2nd and 3rd place at hVIVO's "Winter in Focus" staff photography competition! 📷 1st Place 🥇 Mubeena parveen, Research Assistant 2nd Place 🥈 Cheshma Thilak, Patient & Volunteer Co-Ordinator 3rd Place 🥉 Julie Mori, Principal Virologist Comment below on which is your favourite! #HVO #WinterPhotos #London #Winter #Festive #Christmas
-
-
The UK BioIndustry Association (BIA) CEO Steve Bates OBE FMedSci mentioned our peer-reviewed paper from the world’s first COVID-19 characterisation trial, recently published in Nature Portfolio Communications, in his CEO update & highlighted the ongoing value of this work and its potential use to support future pandemics. Read the full article here: https://lnkd.in/eMME8_5d #HVO #NatureCommunications #COVID #BIA
-
-
Our CEO Yamin 'Mo' Khan Khan will be in San Francisco for J.P. Morgan's 43rd Health Care Conference in January 2025. Reach out via LinkedIn or at bd@hvivo.com to schedule a meeting . #HVO #JPM25 #Healthcare #SanFransisco
-
-
The talented chef and author Thuy Diem Pham visited hVIVO for a culinary and immersive experience! We were delighted to host Thuy, who ran a Vietnamese cooking masterclass straight out of our hKITCHEN! Our staff got hands-on in creating the delicious rolls and volunteers received the same flavourful lunch, prepared by our hKITCHEN team. A big thank you to Thuy for sharing her time and cooking skills with hVIVO! #HVO #Cooking #ESG #MasterChef #CulinaryExperience #FluCamp
-
-
Last week, our Chief Scientific Officer, Dr. Andrew Catchpole, led an insightful seminar on Human Challenge Trials at the UK Health Security Agency. We were delighted to share our expertise on how these trials play a vital role in: ✅ Advancing our understanding of disease progression ✅ Accelerating the development of vaccines & therapeutics Human Challenge Trials play a key role in the fight against infectious and respiratory diseases, and we’re proud to contribute to this ground-breaking work.
-